IMV Inc. (IMV)

NASDAQ: IMV · IEX Real-Time Price · USD
1.05
-0.01 (-0.94%)
May 20, 2022 3:58 PM EDT - Market closed
Market Cap86.38M
Revenue (ttm)112,698
Net Income (ttm)-31.85M
Shares Out82.27M
EPS (ttm)-0.52
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume31,858
Open1.05
Previous Close1.06
Day's Range1.01 - 1.10
52-Week Range0.90 - 2.50
Beta1.88
AnalystsBuy
Price Target4.04 (+284.8%)
Earnings DateMay 13, 2022

About IMV

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and microsatellite instability high tumors, as well as in Phase I clinical trial for breast cancer. It also ...

IndustryBiotechnology
Founded2000
Employees97
Stock ExchangeNASDAQ
Ticker SymbolIMV
Full Company Profile

Financial Performance

In 2021, IMV Inc.'s revenue was 188,000, a decrease of -16.44% compared to the previous year's 225,000. Losses were -36.59 million, 40.4% more than in 2020.

Financial numbers in millions CADFinancial Statements

Analyst Forecast

According to 9 analysts, the average rating for IMV stock is "Buy." The 12-month stock price forecast is 4.04, which is an increase of 284.76% from the latest price.

Price Target
$4.04
(284.76% upside)
Analyst Consensus: Buy
Stock Forecasts

News

IMV Inc. to Present at the H.C. Wainwright Global Investment Conference

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platfo...

4 days ago - Business Wire

IMV Inc. Announces First Quarter 2022 Financial and Operational Results

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platfo...

1 week ago - Business Wire

IMV Inc. to Announce First Quarter 2022 Results and Host a Conference Call and Webcast on May 13, 2022

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating therapies based...

2 weeks ago - Business Wire

IMV's Lead Compound to Be Showcased in Two Presentations at the 2022 ASCO Annual Meeting

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platfo...

3 weeks ago - Business Wire

IMV Inc. Names Michael P. Bailey Chairman of The Board

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating therapies based...

4 weeks ago - Business Wire

IMV Inc. Presents Clinical Benefit of MVP-S in Combination with Pembrolizumab in Bladder Cancer at the AACR Annual Me...

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platfo...

1 month ago - Business Wire

IMV to Present at IMMUNOLOGY™ 2022, the AAI Annual Meeting

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platfo...

1 month ago - Business Wire

IMV Inc. to Present at Two Upcoming Investor Conferences

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platfor...

1 month ago - Business Wire

IMV Inc. Announces Fourth Quarter and Full Year 2021 Financial and Operational Results

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. Announces Fourth Quarter and Full Year 2021 Financial and Operational Results

2 months ago - Business Wire

IMV Inc. to Announce Fourth Quarter and Fiscal Year 2021 Results and Host a Conference Call and Webcast on March 17, ...

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. to Announce Fourth Quarter and Fiscal Year 2021 Results and Host a Conference Call and Webcast on March 17, 2022

2 months ago - Business Wire

IMV to Showcase its DPX® Delivery Technology in Two Presentations at the AACR Annual Meeting 2022

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platfor...

2 months ago - Business Wire

IMV to Host a Webcast to Highlight its Immune-Educating DPX® Platform

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platfor...

3 months ago - Business Wire

IMV Doses First Patient in the Mid-Stage Study With Keytruda

IMV (IMV) doses first patient in the phase II study evaluating lead compound, maveropepimut-S (MVP-S), in combination with Keytruda

4 months ago - Zacks Investment Research

Horizon Technology Finance Provides Fourth Quarter 2021 Portfolio Update

FARMINGTON, Conn., Jan. 12, 2022 /PRNewswire/ -- Horizon Technology Finance Corporation (NASDAQ: HRZN) ("HRZN" or the "Company"), a leading specialty finance company that provides capital in the form of...

Other symbols:HRZN
4 months ago - PRNewsWire

IMV Announces First Patient Dosed in the VITALIZE Phase 2B Clinical Study Evaluating its Lead Compound, MVP-S, in Com...

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platfor...

4 months ago - Business Wire

IMV Inc. to Present at Two Upcoming Investor Events

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. to Present at Two Upcoming Investor Events

4 months ago - Business Wire

IMV Appoints Andrew Hall as Chief Executive Officer

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Appoints Andrew Hall as Chief Executive Officer

4 months ago - Business Wire

IMV Announces Finalization of the Basket Clinical Study in Collaboration with Merck and Reveals Promising Top Line Da...

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX™ platfo...

5 months ago - Business Wire

IMV Strengthens its Financial Position with the Completion of a US$25 Million Long-Term Debt Facility

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Strengthens its Financial Position with the Completion of a US$25 Million Long-Term Debt Facility

5 months ago - Business Wire

Role of B Cells Induced by IMV's Lead Compound in Patients with Ovarian Cancer to be Showcased at the ESMO-IO Congress

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX™ platfo...

5 months ago - Business Wire

IMV Announces First Patient Dosed in Phase 1b Clinical Study Evaluating its Lead Compound in Patients with Breast Cancer

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX platfor...

5 months ago - Business Wire

IMV Inc. to Present at the Piper Sandler Virtual Healthcare Conference

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (Nasdaq: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating cancer therapie...

5 months ago - Business Wire

IMV Inc. Announces Chief Financial Officer to Retire

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)--IMV Inc. (NASDAQ: IMV; TSX: IMV) (“IMV” or “the Company”), a clinical-stage company developing a portfolio of immune-educating cancer therapie...

5 months ago - Business Wire

IMV Inc. Announces Third Quarter 2021 Financial and Operational Update

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #DeliveryPlatform--IMV Inc. (“IMV” or “the Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing immune-educating can...

6 months ago - Business Wire

Translational Data From the DeCidE1 Clinical Study in Patients with Advanced, Recurrent Ovarian Cancer to be Presente...

DARTMOUTH, Nova Scotia, & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #DeliveryPlatform--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies ba...

6 months ago - Business Wire